A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Th...
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. In order to fill this gap in policy research, the objective of this study...
Alternative Titles
Full title
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3996169
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3996169
Other Identifiers
ISSN
1472-6963
E-ISSN
1472-6963
DOI
10.1186/1472-6963-14-170
